Stevens Capital Management LP Buys Shares of 3,967 Biogen Inc. $BIIB

Stevens Capital Management LP purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,967 shares of the biotechnology company’s stock, valued at approximately $556,000.

Several other institutional investors have also recently made changes to their positions in BIIB. Elevation Point Wealth Partners LLC purchased a new stake in Biogen in the second quarter worth about $25,000. Rothschild Investment LLC increased its position in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the period. True Wealth Design LLC raised its holdings in shares of Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares in the last quarter. NewSquare Capital LLC raised its holdings in shares of Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares in the last quarter. Finally, WFA of San Diego LLC purchased a new stake in shares of Biogen in the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 0.0%

Biogen stock opened at $192.03 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a market cap of $28.18 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16. The stock has a 50-day moving average of $180.02 and a two-hundred day moving average of $161.29. Biogen Inc. has a one year low of $110.04 and a one year high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% on a year-over-year basis. During the same period last year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BIIB. TD Cowen boosted their price objective on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Wedbush boosted their price target on Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Guggenheim raised their price objective on Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research report on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Finally, Morgan Stanley set a $190.00 price target on shares of Biogen in a report on Sunday, February 8th. Twelve equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and a consensus price target of $205.04.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.